Investor Centre

The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have

With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is

At Anteris we bring

The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.

The proven benefits of our ADAPT^® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to

At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.